PTGS2 and COVID-19: Currently, cyclooxygenase inhibition through either tNSAIDs or COXIBs in order to reduce the cytokine storm and systemic inflammation in COVID-19 is a frequently investigated topic, and has to be discussed with regard to a potentially suppressed immune response due to COX-2 inhibition.